Year Established :
2018
Total Assets(USD) :
500,000 to 99,999,999
Total Number of Staff :
100-500
Main Competitive Advantages :
Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Quality Service
Other Competitive Advantages :
We have our own R&D Center. The R&D Center covers an area of 1500m2, with complete procedures, equipment and facilities and perfect functions. It can complete all kinds of synthetic reactions with a volume of 250ml-3000L, also equips with dozens of testing equipments, such as, Shimadzu, Agilent chromatograph and other types. It is equipped with 30 professional R & D personnel, including 1 doctor, 5masters, 1 "Taishan Industry leader", 8 person with intermediate titles.
Business Type :
Trading Company,Manufacturer
R&D Capacity :
OEM,ODM,Own Brand
Annual Turnover(USD) :
500,000 to 99,999,999
Main Sales Markets :
Central/South America,Western Europe,Eastern Europe,Asia,Middle East
Product Range :
Our main products are pharmaceutical intermediates and some fine chemicals: Indapamide's intermediates, AZD9291(Osimertinib)'s intermediates, Raltegravir's intermediate, Buspirone's intermediates, Upadacitinib's intermediate, Crisaborole's intermediate, Deucravacitinib's intermediate and other intermediates.
One year of qualification
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
